It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s).
JNJ (@Pharmaceuticals: Major) experienced а -2.96% price change this week, while PFE (@Pharmaceuticals: Major) price change was +1.47% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.89%. For the same industry, the average monthly price growth was -4.31%, and the average quarterly price growth was -3.13%.
JNJ is expected to report earnings on Oct 17, 2023.
PFE is expected to report earnings on Oct 31, 2023.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
|JNJ||PFE||JNJ / PFE|
overvalued / fair valued / undervalued
PROFIT vs RISK RATING
PRICE GROWTH RATING
P/E GROWTH RATING
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (4) in the Pharmaceuticals Major industry is in the same range as JNJ (20). This means that PFE’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (25) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (96). This means that JNJ’s stock grew significantly faster than PFE’s over the last 12 months.
PFE's SMR Rating (43) in the Pharmaceuticals Major industry is in the same range as JNJ (53). This means that PFE’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (56) in the Pharmaceuticals Major industry is in the same range as PFE (64). This means that JNJ’s stock grew similarly to PFE’s over the last 12 months.
JNJ's P/E Growth Rating (30) in the Pharmaceuticals Major industry is in the same range as PFE (59). This means that JNJ’s stock grew similarly to PFE’s over the last 12 months.
2 days ago48%
2 days ago66%
2 days ago57%
2 days ago63%
2 days ago52%
2 days ago56%
2 days ago43%
2 days ago51%
2 days ago41%
2 days ago56%
2 days ago37%
2 days ago57%
18 days ago42%
2 days ago42%
3 days ago59%
2 days ago61%
2 days ago45%
2 days ago34%
2 days ago56%
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with MRK. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then MRK could also see price increases.